Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Mobic was the original U.S. trade-name product containing meloxicam, a prescription nonsteroidal anti-inflammatory drug. Its 7.5 mg and 15 mg tablets were used for osteoarthritis, rheumatoid arthritis, and selected juvenile rheumatoid arthritis. The original Mobic tablets have been discontinued from U.S. marketing for reasons unrelated to safety or effectiveness. Generic meloxicam products remain available.
read more about what was mobic ...Meloxicam inhibits cyclooxygenase enzymes involved in the production of prostaglandins. These substances contribute to pain, inflammation, and swelling. By reducing prostaglandin synthesis, Mobic relieved inflammatory symptoms associated with arthritis without correcting the underlying joint disorder.
Mobic tablets were prescribed for adults with osteoarthritis or rheumatoid arthritis and for selected pediatric patients with pauciarticular or polyarticular juvenile rheumatoid arthritis weighing at least 60 kg. Patients with a history of serious allergic reactions to aspirin or other nonsteroidal anti-inflammatory medicines could not receive Mobic. Generic meloxicam remains an option under current prescribing information.
The usual adult starting and maintenance dose was 7.5 mg once daily for osteoarthritis or rheumatoid arthritis. The dose could increase to 15 mg once daily according to response, with a maximum adult daily dose of 15 mg. For juvenile rheumatoid arthritis, the tablet dose was 7.5 mg once daily in eligible children weighing at least 60 kg. Different meloxicam formulations have separate dosing and substitution instructions.
Mobic carried boxed warnings for potentially fatal cardiovascular thrombotic events, including heart attack and stroke, and serious gastrointestinal bleeding, ulcers, or perforation. Other risks included kidney injury, worsening heart failure, high blood pressure, liver injury, severe skin reactions, and fetal toxicity. Use around coronary artery bypass graft surgery was contraindicated. These class-related risks also apply to current meloxicam products.
Mobic treated osteoarthritis, rheumatoid arthritis, and selected juvenile rheumatoid arthritis.
Mobic contained meloxicam, a nonsteroidal anti-inflammatory drug.
The original Mobic tablets were discontinued from U.S. marketing, but generic meloxicam remains available.
Yes. Mobic carried boxed warnings for serious cardiovascular events and gastrointestinal bleeding, ulceration, and perforation.
DailyMed - MELOXICAM tablet. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e0deb1f7-b575-463f-a3f8-304cc1936075. Date Accessed October 14, 2026.
Determination That MOBIC (Meloxicam) Tablets, 7.5 Milligrams and 15 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. U.S. Food and Drug Administration. https://federalregister.gov/d/2025-06783. Date Accessed October 14, 2026.
Meloxicam. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548278/. Date Accessed October 14, 2026.
Meloxicam. MedlinePlus. https://medlineplus.gov/druginfo/meds/a601242.html. Date Accessed October 14, 2026.
MOBIC (meloxicam tablets) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/020938s030lbl.pdf. Date Accessed October 14, 2026.